126 related articles for article (PubMed ID: 24182219)
41. A clinical dilemma; single prostatic cancer focus in biopsy. Interpretation and management.
Efthimiou I; Skrepetis K; Bournia E
J BUON; 2010; 15(1):19-24. PubMed ID: 20414922
[TBL] [Abstract][Full Text] [Related]
42. Editorial for "Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50".
Andriole GL; Kibel AS
Cancer; 2011 Mar; 117(6):1110-2. PubMed ID: 20960524
[No Abstract] [Full Text] [Related]
43. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
44. Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
Augustin H; Mayerhofer K; Seles M; Pummer K
Urol Int; 2015; 95(2):125-31. PubMed ID: 25791432
[TBL] [Abstract][Full Text] [Related]
45. Prostate cancer screening "reloaded".
Gomella LG
Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
[No Abstract] [Full Text] [Related]
46. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
47. Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.
Etzioni R; Gulati R
JAMA Oncol; 2016 Jul; 2(7):955-6. PubMed ID: 27010657
[No Abstract] [Full Text] [Related]
48. The role of multi-parametric MRI in loco-regional staging of men diagnosed with early prostate cancer.
Appayya MB; Johnston EW; Punwani S
Curr Opin Urol; 2015 Nov; 25(6):510-7. PubMed ID: 26372039
[TBL] [Abstract][Full Text] [Related]
49. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
Narayan VM; Konety BR; Warlick C
Int J Urol; 2017 May; 24(5):352-360. PubMed ID: 28345187
[TBL] [Abstract][Full Text] [Related]
50. A guideline to clinical utility of prostate specific antigen.
Farhat WA; Habbal AA; Khauli RB
Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789
[TBL] [Abstract][Full Text] [Related]
51. Prostate cancer screening perspective, Malaysia.
Sothilingam S; Sundram M; Malek R; Sahabuddin RM
Urol Oncol; 2010; 28(6):670-2. PubMed ID: 21062649
[TBL] [Abstract][Full Text] [Related]
52. In the Clinic. Prostate Cancer.
Talcott JA
Ann Intern Med; 2015 Dec; 163(11):ITC1-12. PubMed ID: 26618297
[No Abstract] [Full Text] [Related]
53. Application of prostate-specific antigen in prostate cancer.
Liang SL
MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
[No Abstract] [Full Text] [Related]
54. Community-Based Screening for Prostate Cancer: A Role for Magnetic Resonance Imaging?
Lee SI; O'Shea A
JAMA Oncol; 2021 Mar; 7(3):402-403. PubMed ID: 33570559
[No Abstract] [Full Text] [Related]
55. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
Braillon A; Dubois G
J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
[No Abstract] [Full Text] [Related]
56. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
57. Conundrums in screening for cancer.
Miller AB
Int J Cancer; 2010 Mar; 126(5):1039-46. PubMed ID: 19960430
[TBL] [Abstract][Full Text] [Related]
58. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
[TBL] [Abstract][Full Text] [Related]
59. Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
Schröder FH; Roobol MJ
BJU Int; 2009 Jan; 103(2):143-4. PubMed ID: 19076150
[No Abstract] [Full Text] [Related]
60. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
